GlassScriptPhysician profile
Sudip N Ringwala
NPI 1588956197
$5,864.11
in general payments reported to CMS, 2019-2025
31 companies · $1,136 in 2025
The $1,136 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $627 · 2021: $945 · 2022: $1,138 · 2023: $582 · 2024: $735 · 2025: $1,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,428 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,427.51 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,153.71 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $814.09 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $544.30 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $301.82 | 2021-2025 | Cuvitru, Takhzyro, Glassia |
| Optinose US, INC. | $203.52 | 2019-2022 | |
| Amgen INC. | $171.83 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $156.43 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $146.97 | 2019-2025 | Xolair |
| Biocryst US Sales Co., LLC | $128.62 | 2022-2025 | Orladeyo |
| Csl Behring | $118.00 | 2019-2021 | |
| Kaleo, INC. | $104.97 | 2019-2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $95.12 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $93.39 | 2021-2022 | |
| Pfizer INC. | $92.33 | 2019-2021 | |
| Mylan Specialty L.P. | $80.48 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $79.26 | 2025 | Dawnzera |
| Janssen Pharmaceuticals, INC | $70.35 | 2019-2021 | |
| Novo Nordisk INC | $69.18 | 2019-2022 | |
| Leo Pharma INC. | $66.67 | 2025 | Anzupgo, Adbry |
| Alk-Abello, INC | $65.70 | 2019-2022 | |
| Octapharma USA, INC. | $53.92 | 2019-2024 | Cutaquig |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.89 | 2020-2021 | |
| Abbvie INC. | $35.09 | 2021-2022 | |
| Lilly USA, LLC | $32.66 | 2021 | |
| Aimmune Therapeutics, INC. | $32.31 | 2022 | |
| Organon LLC | $28.70 | 2025 | |
| Uswm, LLC | $22.25 | 2021 | |
| Exact Sciences Corporation | $14.94 | 2025 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $13.81 | 2023 | Crysvita |
| Shire North American Group INC | $13.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudip Ringwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.